Cetuximab-induced acneiform eruption and the response to isotretinoin.
Vezzoli
Pamela
P
Marzano
Angelo Valerio
AV
Onida
Franceso
F
Alessi
Elvio
E
Galassi
Barbara
B
Tomirotti
Maurizio
M
Berti
Emilio
E
D017486:Acneiform Eruptions / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D003879:Dermatologic Agents / Q000627:therapeutic use; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012867:Skin / Q000473:pathology
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D066246:ErbB Receptors; D015474:Isotretinoin; D000068818:Cetuximab